Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia

Journal of Interferon and Cytokine Research

Volumn 33, Issue 1, 2013, Pages 34-42

  Lee, Teresa Y ^a   Ezelle, Heather J ^a   Venkataraman, Thiagarajan ^a   Lapidus, Rena G ^a   Scheibner, Kara A ^a   Hassel, Bret A ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 29; RIBONUCLEASE L; SHORT HAIRPIN RNA;

3' UNTRANSLATED REGION; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LEUKEMIA CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENDORIBONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HELA CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUCIFERASES; MICE; MICE, NUDE; MICRORNAS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873619956     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0062     Document Type: Article

References (51)

1. Abdelmohsen K, Gorospe M. 2010. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1(2):214-229.
2. Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, Hariharan M, Scaria V, Lalwani M, Pillai B, Mitra D, Brahmachari SK. 2008. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retro-virology 5:117.
3. Andersen JB, Li XL, Judge CS, Zhou A, Jha BK, Shelby S, Zhou L, Silverman RH, Hassel BA. 2007. Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene 26(21):3081-3088. (Pubitemid 46733645)
4. Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, Brown KE, Burge CB, Schmidt WN, Wang Y, McCaffrey AP. 2011. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 over-expression reduces hepatitis C viral abundance in culture. J Infect Dis 203(12):1753-1762.
5. Baou M, Norton JD, Murphy JJ. 2011. AU-rich RNA binding proteins in hematopoiesis and leukemogenesis. Blood 118(22):5732-5740.
6. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281-297.
7. Betel D, Wilson M, Gabow A, Marks DS, Sander C. 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res 36(Database issue):D149-D153. (Pubitemid 351149712)
8. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T. 1995. Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem 270(22):13308-13317.
9. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Sil-verman RH, Witte JS. 2002. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32(4):581-583. (Pubitemid 35435169)
10. Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, Silverman RH, Youle RJ. 1998. The role of 2¢-5¢ oligoadenylate- activated ribonuclease L in apoptosis. Cell Death Differ 5(4):313-320. (Pubitemid 28356544)
11. Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, Dalakas MC, Torrence PF, Youle RJ. 1997. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 186(6):967-972. (Pubitemid 27407357)
12. Croce C. 2012. Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J 18(3): 213-214.
13. Ezelle HJ, Hassel BA. 2012. Pathologic effects of RNase-L dys-regulation in immunity and proliferative control. Front Biosci (Schol Ed) 4:767-786.
14. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA me-thyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104(40):15805-15810. (Pubitemid 350035380)
15. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. 2009. MicroRNA 29b functions in acute mye-loid leukemia. Blood 114(26):5331-5341.
16. Gebeshuber CA, Zatloukal K, Martinez J. 2009. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10(4):400-405.
17. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC, De Vos J, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R. 2010. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 28(15):2529-2537.
18. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. 1993. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12(8):3297-3304. (Pubitemid 23232761)
19. Hubbell HR, Kariko K, Suhadolnik RJ, Brodsky I. 1994. RNase L and increased endoribonuclease activities in the mononuclear cells of patients with chronic myelogenous leukemia. Anticancer Res 14(2A):341-346. (Pubitemid 24176768)
20. Jha BK, Polyakova I, Kessler P, Dong B, Dickerman B, Sen GC, Silverman RH. 2011. Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J Biol Chem 286(30):26319-26326.
21. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. 2012. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 44(4):237-244.
22. Kubota K, Nakahara K, Ohtsuka T, Yoshida S, Kawaguchi J, Fujita Y, Ozeki Y, Hara A, Yoshimura C, Furukawa H, Har-uyama H, Ichikawa K, Yamashita M, Matsuoka T, Iijima Y. 2004. Identification of 2¢-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon. J Biol Chem 279(36):37832-37841. (Pubitemid 39195498)
23. Larsson LG, Henriksson MA. 2010. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316(8):1429-1437.
24. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115(7):787-798. (Pubitemid 38058492)
25. Li XL, Andersen JB, Ezelle HJ, Wilson GM, Hassel BA. 2007. Post-transcriptional regulation of RNase-L expression is mediated by the 3¢-untranslated region of its mRNA. J Biol Chem 282(11):7950-7960. (Pubitemid 47093551)
26. Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, Hasday JD, Mohapatra SK, Crasta OR, Vogel SN, Cross AS, Hassel BA. 2008. An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proc Natl Acad Sci U S A 105(52):20816-20821.
27. Liu W, Liang SL, Liu H, Silverman R, Zhou A. 2007. Tumour suppressor function of RNase L in a mouse model. Eur J Cancer 43(1):202-209. (Pubitemid 46054467)
28. Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, Nordsmark M, Wiuf C, Hansen LL. 2008. Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS One 3(6):e2492.
29. Malathi K, Dong B, Gale M, Jr., Silverman RH. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448(7155):816-819. (Pubitemid 47266340)
30. Malathi K, Paranjape JM, Bulanova E, Shim M, Guenther-Johnson JM, Faber PW, Eling TE, Williams BR, Silverman RH. 2005. A transcriptional signaling pathway in the IFN system mediated by 2¢-5¢-oligoadenylate activation of RNase L. Proc Natl Acad Sci U S A 102(41):14533-14538. (Pubitemid 41457092)
31. Malathi K, Saito T, Crochet N, Barton DJ, Gale M, Jr., Silverman RH. 2010. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA 16(11):2108-2119.
32. Mott JL, Kobayashi S, Bronk SF, Gores GJ. 2007. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26(42): 6133-6140. (Pubitemid 47414372)
33. Pekarsky Y, Croce CM. 2010. Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 1(3):224-227.
34. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. 2006. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66(24):11590-11593.
35. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. 2004. ON-COMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6(1):1-6. (Pubitemid 38391943)
36. Salehzada T, Cambier L, Vu Thi N, Manchon L, Regnier L, Bisbal C. 2009. Endoribonuclease L (RNase L) regulates the myo-genic and adipogenic potential of myogenic cells. PLoS One 4(10):e7563.
37. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. 2010. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 107(27):12210-12215.
38. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. 2008. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 105(15):5874-5878. (Pubitemid 351758465)
39. Silverman RH. 2007a. A scientific journey through the 2-5A/RNase L system. Cytokine Growth Factor Rev 18(5-6):381-388. (Pubitemid 47302833)
40. Silverman RH. 2007b. Viral encounters with 2¢,5¢-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 81(23):12720-12729. (Pubitemid 350156909)
41. van Kouwenhove M, Kedde M, Agami R. 2011. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11(9):644-656.
42. van Rooij E, Purcell AL, Levin AA. 2012. Developing microRNA therapeutics. Circ Res 110(3):496-507.
43. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. 2002. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RE-SEARCH0034.
44. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103(7):2257-2261. (Pubitemid 43271657)
45. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. 2008. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14(5):369-381.
46. Wang L, Zhou A, Vasavada S, Dong B, Nie H, Church JM, Williams BR, Banerjee S, Silverman RH. 1995. Elevated levels of 2¢,5¢-linked oligoadenylate-dependent ribonuclease L occur as an early event in colorectal tumorigenesis. Clin Cancer Res 1(11):1421-1428.
47. Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P, Gregorevic P. 2011. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 286(16):13805-13814.
48. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. 2010. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115(13):2630-2639.
49. Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72(5):753-765. (Pubitemid 23093883)
50. Zhou A, Molinaro RJ, Malathi K, Silverman RH. 2005. Mapping of the human RNASEL promoter and expression in cancer and normal cells. J Interferon Cytokine Res 25(10):595-603. (Pubitemid 41507815)
51. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. 1997. Interferon action and apoptosis are defective in mice devoid of 2¢,5¢-oligoadenylate-dependent RNase L. EMBO J 16(21):6355-6363. (Pubitemid 27483262)